Lanthanum carbonate tablets recalled in a second hardness specification failure
Cipla USA is recalling 1,180 boxes of Lanthanum Carbonate chewable tablets, 1000mg, from a further lot after an out of specification hardness test result.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 because the record cites an out of specification stability result with no stated clinical consequence or reported harm.
Plain-English summary
Lanthanum Carbonate chewable tablets, 1000mg, supplied as 10 x 9 bottles per patient pack carton, are being recalled. The prescription product is manufactured by Invagen Pharmaceuticals, Inc. of Hauppauge, New York, for Cipla USA, Inc. of Warren, New Jersey.
The recall follows failed stability specifications: an out of specification result on the hardness test.
This record covers 1,180 boxes from lot NB240315, expiry 12/31/2025. Distribution was nationwide in the USA. The FDA has classified the action as Class II.
The record describes a stability testing failure rather than a reported patient harm. Patients should not stop taking a prescribed medicine without speaking to their prescriber or pharmacist, who can confirm whether a specific pack is affected.
The recalled product
- Product
- LANTHANUM CARBONATE (LANTHANUM CARBONATE)
- Brand
- LANTHANUM CARBONATE
- Manufacturer
- Cipla USA, Inc.
- Category
- Drug — Phosphate binder
- Affected units
- 1,180
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- lot# NB240315
- exp 12/31/2025
UPCs (3)
- 0369097935894
- 0369097936655
- 0369097934576
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Cipla USA, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LANTHANUM CARBONATE
- CriticalFrozen jamun recalled after the product tested positive for Salmonella
FDA (Drugs) · 2025-12-17
Same manufacturer · Cipla USA, Inc.
See all →- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCisatracurium 20 mg multiple-dose vials recalled after subpotent assay results
FDA (Drugs) · 2025-12-24